RSS-Feed abonnieren
DOI: 10.1055/s-2003-39747
Liquorfiltration als experimentelle Therapie bei therapieresistenten Psychosen Borna-Disease-Virus-seropositiver Patienten
Therapeutische Effekte, BefundeCSF Filtration as Experimental Therapy in Therapyresistant Psychoses in Borna Disease Virus-Seropositive PatientsTherapeutic Effects, Findings Diese Forschungen wurden unterstützt durch die Theodore and Vada Stanley-Foundation, Bethesda/USAPublikationsverlauf
Publikationsdatum:
04. Juni 2003 (online)
Zusammenfassung
Eine milde Borna-Disease-Virus-Enzephalitis mag einer Subgruppe affektiver oder schizophrener Spektrumpsychosen zugrunde liegen. Deshalb haben wir vier BDV-seropositive Patienten mit therapieresistenten schizophrenen oder affektiven Psychosen in einer experimentellen Add-on-Therapie mit Liquorfiltration (CSFF) behandelt. CSFF stellt eine effektive immunmodulatorische Therapie bei Guillain-Barré-Syndrom, einer autoimmuninflammatorischen neurologischen Erkrankung, dar. CSFF erscheint nach diesen ersten Ergebnissen auch bei therapieresistenten Psychosen effektiv zu sein.
Abstract
According to previous investigations, mild Borna disease virus encephalitis may underlie a subgroup of affective or schizophrenic type psychoses. And virus-induced immune pathology may underlie even a larger subgroup of psychoses. We treated BDV seropositive patients suffering from therapy resistant schizophrenic or affective spectrum psychoses by cerebrospinal fluid filtration (CSFF) in an experimental add-on treatment. CSFF was shown previously to be an effective immune modulatory treatment in autoimmune neurological disease, Guillain-Barré syndrome. CSFF appears to be an effective treatment in therapy resistant psychosis also, but only 4 patients were treated yet.
Literatur
-
1 Bechter K.
Borna Disease Virus. Mögliche Ursache neurologischer und psychiatrischer Störungen des Menschen. In: Hippius H, Janzarik W, Müller C Monographien aus dem Gesamtgebiete Psychiatrie. Darmstadt; Steinkopff 1998 - 2 Herzog S, Rott R. Replication of Borna disease virus in cell cultures. Med Microbiol Immunol. 1980; 168 153-158
- 3 Richt J A, Alexander R C, Herzog S, Hooper D C, Kean R, Spitsin S, Bechter K, Schüttler R, Feldmann H, Heiske A, Fu Z F, Dietzschold B, Rott R, Koprowski H. Failure to detect Borna disease virus infection in peripheral blood leukocytes from humans with psychiatric disorders. J Neurovirol. 1997; 3 174-178
- 4 Herzog S, Pfeuffer I, Haberzettl K, Feldmann H, Frese K, Bechter K, Richt J A. Molecular characterization of Borna disease virus from naturally infected animals and possible links to human disorders. Arch Virol. 1997; 131 (Suppl) 183-190
- 5 Nübling C M, Kurth R. and Borna Virus Study Group .Abstracts of the Borna Virus Meeting. Freiburg/Germany; 27. - 29. Sept. 1998
- 6 Ludwig H, Bode L. Borna disease virus: new aspects on infection, disease, diagnosis and epidemiology. Rev Sci Tech. 2000; 19 259-288
- 7 Richt J A, Rott R. Borna disease virus: a mystery as an emerging zoonotic pathogen. Vet J. 2001; 161 24-40
- 8 Carbone K M. Borna disease virus and human disease. Clin Microbiol Rev. 2001; 14 513-527
- 9 Lieb K, Staeheli P. Borna disease virus - does it infect humans and cause psychiatric disorders?. Rev Clin Virol. 2001; 21 119-127
- 10 Schwemmle M. Borna disease virus infection in psychiatric patients: are we on the right track?. Lancet Infect Dis. 2001; 1 46-52
- 11 Bechter K. Mild encephalitis underlying psychiatric disorder - A reconsideration and hypothesis exemplified on Borna disease. Neurol Psychiatry Brain Res. 2001; 9 1-16
- 12 Herzog S, Frese K, Richt J A, Rott R. Ein Beitrag zur Epizootiologie der Bornaschen Krankheit beim Pferd. Wien Tierärztl Mschr. 1994; 81 374-379
- 13 Reiber H. Cerebrospinal fluid - physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler. 1998; 4 99-107
- 14 Bechter K, Herzog S, Behr W, Schüttler R. Investigations of cerebrospinal fluid in Borna disease virus seropositive psychiatric patients. Eur Psychiatry. 1995; 10 250-258
- 15 Wollinsky K H, Hülser P J, Brinkmeier H, Mehrkens H H, Kornhuber H H, Rüdel R. Filtration of cerebrospinal fluid in acute inflammatory demyelinating polyneuropathy (Guillain-Barré syndrome). Ann Med Interne. 1994; 145 451-458
- 16 Wollinsky K H, Hülser P J, Brinkmeier H, Aulkemeyer P, Bössenecker W, Huber-Hartmann K H, Rohrbach P, Schreiber H, Weber F, Kron M, Büchele G, Mehrkens H H, Ludolph A C, Rüdel R. CSF filtration is an effective treatment of Guillain-Barré syndrome: A randomized clinical trial. Neurology. 2001; 57 774-780
-
17 Rott R, Becht H.
Natural and Experimental Borna Disease in Animals. In: Koprowski H, Lipkin WI (eds) Borna Disease. Curr Top Microbiol Immunol. Berlin; Springer 1995: 17-30 - 18 Bilzer T, Stitz L. Immunopathogenesis of virus disease affecting the central nervous system. Crit Rev Immunol. 1996; 16 145-222
-
19 Bechter K, Herzog S, Schreiner V, Wollinsky K H, Schüttler R.
Cerebrospinal fluid filtration in a case of schizophrenia related to „subclinical” Borna disease virus encephalitis. In: Müller N Psychiatry, Psychoneuroimmunology, and Viruses. Key Top Brain Res. Wien; Springer 1999: 19-35 - 20 Peuskens J. The evolving definition of treatment resistance. J Clin Psychiatry. 1999; 60 (Suppl 12) 4-8
- 21 Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, Racagni G, Zohar J, Mendlewicz J. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999; 9 83-91
- 22 Weber F, Brinkmeier H, Aulkemeyer P, Wollinsky K H, Rüdel R. A small sodium channel blocking factor in the cerebrospinal fluid is preferentially found in Guillain-Barré syndrome: a combined cell physiological and HPLC study. J Neurol. 1999; 246 955-960
- 23 Aulkemeyer P, Hausner G, Brinkmeier H, Weber F, Würz A, Heidenreich F, Rüdel R. The small sodium-channel blocking factor in the cerebrospinal fluid of multiple sclerosis patients is probably an oligopeptide. J Neurol Sci. 2000; 172 49-54
- 24 Brinkmeier H, Aulkemeyer P, Wollinsky K H, Rüdel R. An endogenous pentapeptide acting as a sodium channel blocker in inflammatory autoimmune disorders of the central nervous system. Nature Med. 2000; 6 808-811
- 25 Oleszak E L, Kuzmak J, Hogue B, Parr R, Collisson E W, Rodkey L S, Leibowitz J L. Molecular mimicry between Fc receptor and S peplomer protein of mouse hepatitis virus, bovine corona virus, and transmissible gastroenteritis virus. Hybridoma. 1995; 14 1-8
- 26 Oleszak E, Lin W L, Chang J R, Herzog S, Bechter K. Clonally expanded T cells are present in the CSF of patients with major depression. World J Biol Psychiatry. 2001; 2 60
- 27 Rother S, Knoblauch K D, Kirschfink M. Filtration of liquor cerebrospinalis (CSF-filtration): technical concept and filter performance under in vitro conditions. Neuropsychiatrie. 1995; 9 82-85
- 28 Waxman S G. Do „demyelinating” diseases involve more than myelin?. Nature Med. 2000; 6 738-739
- 29 Meeker R B, Robertson K, Barry T, Hall C. Neurotoxicity of CSF from HIV-infected humans. J Neurovirol. 1999; 5 507-518
- 30 Xiong H, Zeng Y C, Zheng J, Thylin M, Gendelman H E. Soluble HIV-1 infected macrophage secretory products mediate blockade of long-term potentiation: a mechanism for cognitive dysfunction in HIV-1-associated dementia. J Neurovirol. 1999; 5 519-528
- 31 Kienle G S, Kiene H. The powerful placebo effect: fact or fiction?. J Clin Epidemiol. 1997; 50 1311-1318
- 32 Hróbjartsson A, Gotzsche P C. Is the placebo powerless?. N Eng J Med. 2001; 344 1594-1602
CA Prof. Dr. Karl Bechter
Abteilung Psychiatrie II der Universität Ulm
Ludwig-Heilmeyer-Straße 2
89312 Günzburg
eMail: dr.bechter@bkh-guenzburg.de